5-HT2C R blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain

Stéphanie Grégoire and Volker Neugebauer*

Abstract

Background: Pain, including arthritic pain, has a negative affective component and is often associated with anxiety and depression. However, selective serotonin reuptake inhibitor antidepressants (SSRIs) show limited effectiveness in pain. The amygdala plays a key role in the emotional-affective component of pain, pain modulation and affective disorders. Neuroplasticity in the basolateral and central amygdala (BLA and CeA, respectively) correlate positively with pain behaviors. Evidence suggests that serotonin receptor subtype 5-HT2C R in the amygdala contributes critically to anxiogenic behavior and anxiety disorders. In this study, we tested the hypothesis that 5-HT2C R in the amygdala accounts for the limited effectiveness of SSRIs in reducing pain behaviors and that 5-HT2C R blockade in the amygdala renders SSRIs effective.

Results: Nocifensive reflexes, vocalizations and anxiety-like behavior were measured in adult male Sprague–Dawley rats. Behavioral experiments were done in sham controls and in rats with arthritis induced by kaolin/carrageenan injections into one knee joint. Rats received a systemic (i.p.) administration of an SSRI (fluvoxamine, 30 mg/kg) or vehicle (sterile saline) and stereotaxic application of a selective 5-HT2C R antagonist (SB242084, 10 μM) or vehicle (ACSF) into BLA or CeA by microdialysis. Compared to shams, arthritic rats showed decreased hindlimb withdrawal thresholds (increased reflexes), increased duration of audible and ultrasonic vocalizations, and decreased open-arm choices in the elevated plus maze test suggesting anxiety-like behavior. Fluvoxamine (i.p.) or SB242084 (intra-BLA) alone had no significant effect, but their combination inhibited the pain-related increase of vocalizations and anxiety-like behavior without affecting spinal reflexes. SB242084 applied into the CeA in combination with systemic fluvoxamine had no effect on vocalizations and spinal reflexes.

Conclusions: The data suggest that 5-HT2C R in the amygdala, especially in the BLA, limits the effectiveness of SSRIs to inhibit pain-related emotional-affective behaviors.

Keywords: Amygdala, Pain, Serotonin, SSRI, 5-HT2C R, Emotional-affective behavior, Anxiety

Background

Pain is a multidimensional experience that includes not only sensory-discriminative but also emotional-affective and cognitive components [1,2]. Certain antidepressants have become part of the therapeutic strategy for different types of persistent pain, including neuropathic pain, fibromyalgia, low back pain and headache [3-6], and they are also considered for osteoarthritis pain [7]. Selective serotonin reuptake inhibitor antidepressants (SSRIs) have low or inconsistent analgesic efficacy [4,6] but better overall safety and tolerability compared to tricyclic antidepressants [8].

The serotonergic system has long been known to play an important role in pain modulation [9,10]. The family of at least 14 serotonin (5-HT) receptor subtypes is divided into seven groups (5-HT1R – 5-HT7R) based on their structural and functional characteristics [11-13]. The heterogeneity of 5-HT receptors is believed to account for the differential inhibitory or excitatory effects of 5-HT in the descending pain modulatory systems [9]. 5-HT2C receptor (5-HT2C R) has emerged as a major target for improved treatment of neuropsychiatric disorders.
such as anxiety disorders [14-16]. 5-HT₂CR has also been implicated in adverse effects of 5-HT and SSRIs [14] and in inconsistent clinical efficacy of SSRIs in neuropathic pain [17]. 5-HT₂CR is a G₄₁₁ protein-coupled receptor expressed in GABAergic, glutamatergic, and dopaminergic neurons [18,19]. Thus, 5-HT₂CR can regulate the release of different transmitters to modulate excitatory and inhibitory neurotransmission [20-22]. 5-HT₂CR mRNA and protein show widespread distribution in the human and rat brain, including in the amygdala where particularly high levels are found in the lateral-basolateral area [23,24].

The amygdala, a subcortical area known for its key role in emotions and affective disorders [25], is now recognized as an important neural substrate for the emotional-affective dimension of pain based on preclinical studies from our group [for reviews see [26,27]] and others [28-31] and clinical work [32,33]. Amygdala activity correlates positively with pain behaviors in animals. Increases of amygdala activity can elicit or enhance pain responses even in the absence of tissue injury [34-41]. Conversely, deactivation of the amygdala inhibits pain in different animal models [28,42-49]. Recent studies in humans also show increased amygdala activity in experimental and clinical pain [50-54]. The amygdala circuitry that contributes to emotional-affective aspects of pain is centered on the lateral-basolateral (LA-BLA) and central (CeA) nuclei [26,27]. The CeA receives nociceptive information through a direct pathway from the spinal cord and brainstem (external lateral parabrachial area) and highly processed affect-related information through an indirect pathway from the LA-BLA network via posterior thalamus [26,27]. Neuroplasticity characterized by enhanced excitatory transmission [44,45,55-61] and loss of inhibitory control [61,62] develops in this circuitry in models of inflammatory and neuropathic pain. As a result, abnormally enhanced CeA output generates emotional-affective behaviors and modulates nociceptive responses through direct and indirect projections to brainstem and forebrain areas [26,27].

The amygdala receives a strong serotonergic projection from the dorsal raphe nucleus [63,64], which exerts excitatory and inhibitory effects on neuronal activity through different receptor subtypes [65,66]. There is evidence for increased 5-HT release in the amygdala (BLA) in aversive states [16,67,68]. 5-HT₂CR in the BLA but not CeA contributes critically to anxiogenic behavior and anxiety disorders [15,16,69] and mediates anxiogenic side effects of acutely administered antidepressants such as SSRIs [47,70,71]. Synaptic and cellular effects of 5-HT₂CR in the amygdala are largely unknown but 5-HT₂CR activation in the BLA facilitated NMDA receptor-mediated synaptic plasticity in BLA neurons [72] and induction of hippocampal LTP [73], suggesting that 5-HT₂CR can control amygdala output. In this study, we tested the hypothesis that 5-HT₂CR in the amygdala (BLA but not CeA) contributes to the limited effectiveness of SSRIs on pain behaviors and that blockade of 5-HT₂CR in the BLA renders SSRIs effective in reducing emotional-affective behaviors in a model of arthritis pain. To do so we applied a selective 5-HT₂CR antagonist (SB242084 [74]) stereotaxically into BLA or CeA and administered a selective SSRI (fluvoxamine [75]) systemically (intraperitoneally, i.p.). The effect of each drug alone and of their combined application was determined.

Results

Spinal reflexes (hindlimb withdrawal thresholds), audible and ultrasonic vocalizations, and anxiety-like behavior in the elevated plus maze (EPM) were measured in adult male Sprague Dawley rats with (n = 61) or without (n = 38) arthritis. Arthritic pain was induced by intraarticular injections of kaolin and carrageenan into the left knee joint. Sham rats were handled the same way as arthritic rats but the needle was inserted into the knee without injecting any compounds (see Methods). Behaviors and drug effects were measured 5–6 h after arthritis induction or needle insertion (shams). Drugs or vehicle were administered systemically (i.p.) and stereotaxically into the right basolateral (BLA) or central (CeA) nuclei of the amygdala (see Figure 1). Each animal was tested with only one drug regimen. Audible and ultrasonic vocalizations were measured simultaneously (see Methods) and spinal reflex thresholds were also determined in these animals (counter-balanced for order of tests). EPM performance was tested in separate groups of animals.

Co-application of intra-BLA SB242084 and systemic fluvoxamine decreased vocalizations and anxiety-like behavior of arthritic rats.

Audible vocalizations

Audible vocalizations evoked by innocuous (300 g/30 mm²) and noxious (1200 g/30 mm²) compression of the knee for 15 s were measured in sham controls (Figure 2A and 2C) and in arthritic rats (Figure 2B and 2D). In sham rats, the following drug regimen had no effect on the duration of audible vocalizations compared to vehicle (n = 6 rats): stereotaxic application of a selective 5-HT₂CR antagonist (SB242084 [74], 10 μM, concentration in microdialysis fiber) into BLA together with systemic vehicle administration (n = 7 rats); systemic administration of a selective SSRI (fluvoxamine [75], 30 mg/kg, i.p.) together with ACSF vehicle application into BLA (n = 7 rats); and combined application of systemic fluvoxamine and intra-BLA SB242084 (n = 7 rats). Arthritic rats showed increased audible vocalizations to normally innocuous (Figure 2B) and noxious (Figure 2D) stimuli, reflecting allodynia and hyperalgesia, respectively (see vehicle-treated group, n = 7 rats). Intra-BLA application of SB242084 (10 μM, n = 6)
or systemic administration of fluvoxamine (30 mg/kg, i.p., n = 5) had no effect on audible vocalizations of arthritic rats. However, the combination of intra-BLA SB242084 and systemic fluvoxamine (n = 7) significantly decreased the duration of audible vocalizations to innocuous (P < 0.001) and noxious stimuli (P < 0.01, Dunnett’s multiple comparison tests), reversing the effect of arthritis. The data suggest that 5-HT$_{2C}$R blockade allows an SSRI to inhibit higher integrated pain behaviors.

**Ultrasonic vocalizations**

Ultrasonic vocalizations evoked by innocuous (300 g/30 mm$^2$) and noxious (1200 g/30 mm$^2$) stimulation of the knee joint were measured in sham control (Figure 3A and 3C) and arthritic rats (Figure 3B and 3D). In sham rats, none of the drug regimen (SB242084, 10 μM, n = 7; fluvoxamine, 30 mg/kg, n = 7; co-application of SB242084 and fluvoxamine, n = 7 rats) had a significant effect on the duration of ultrasonic vocalizations compared to vehicle (n = 6 rats). Arthritic rats showed increased vocalizations to normally innocuous (Figure 3B) and noxious (Figure 3D) stimuli (see vehicle-treated group, n = 7 rats). The combination of intra-BLA SB242084 and systemic fluvoxamine (n = 7) inhibited ultrasonic vocalizations significantly (P < 0.001, Dunnett’s multiple comparison tests) compared to vehicle (n = 7 rats). SB242084 alone had no effect (n = 6) and fluvoxamine alone inhibited ultrasonic vocalizations to noxious stimuli slightly but significantly (n = 5, P < 0.05). The data suggest that 5-HT$_{2C}$R blockade induces or enhances the ability of an SSRI to inhibit affective pain behaviors.

**Anxiety-like behavior and locomotion**

Open-arm choice in the elevated plus maze (EPM) was measured for 5 min in sham control rats and in arthritic rats as a negative indicator of anxiety-like behavior [76]. Compared to sham controls (n = 6), arthritic animals (n = 6) showed decreased preference for the open arms indicating an increase in anxiety-like behavior in the pain state (see vehicle control groups in Figure 4A and 4B). The combination of intra-BLA SB242084 (10 μM) and systemic fluvoxamine (30 mg/kg) had no effect compared to vehicle (n = 6) but increased the open-arm choice of arthritic rats (n = 6) compared to vehicle (n = 6) significantly (P < 0.05, Dunnett’s multiple comparison tests), suggesting an anxiolytic effect in the pain state. Intra-BLA SB242084 (n = 7) or systemic fluvoxamine (n = 7) alone had no significant effect in arthritic rats. Compared to sham controls (n = 6), arthritic rats (n = 6) showed decreased exploratory behaviour measured as the total number of entries into the open and closed arms of the EPM for 30 min (Figure 4C). None of the drug regimen (SB242084, 10 μM, n = 7; fluvoxamine, 30 mg/kg, n = 7;
co-application of SB242084 and fluvoxamine, n = 6 rats) had a significant effect on locomotor activity in arthritic rats. In sham controls, only the combination of SB242084 and fluvoxamine was tested and had no significant effect on locomotor activity (n = 5).

**Co-application of intra-BLA SB242084 and systemic fluvoxamine had no effect on spinal reflexes.**

Thresholds of hindlimb withdrawal reflexes evoked by mechanical compression of the knee joint were measured in sham controls (Figure 5A) and arthritic rats (Figure 5B). Compared to controls (n = 6 rats) arthritic rats (n = 7) had decreased thresholds, reflecting increased spinally organized reflexes and mechanical hypersensitivity (see vehicle groups in Figure 5A and 5B). None of the drug regimen had a significant effect in control rats (SB242084, 10 μM, n = 7; fluvoxamine, 30 mg/kg, n = 7; co-application of SB242084 and fluvoxamine, n = 7 rats) and in arthritic rats (SB242084, n = 6; fluvoxamine, n = 5; co-application of SB242084 and fluvoxamine, n = 7 rats). The data suggest that blockade of 5-HT2CR in the BLA allowed the serotonergic system to affect supraspinally but not spinally organized behaviors.

**Co-application of intra-CeA SB242084 and systemic fluvoxamine had no effect on vocalizations in arthritic rats.**

Since the CeA serves as a major output nucleus for amygdala function related to pain modulation, we tested if 5-HT2CR also played a role in this nucleus (Figure 6). We only tested the combination of SB242084 and fluvoxamine since the previous results showed that fluvoxamine alone and SB242084 applied into BLA had no effect. We also performed these tests in arthritic animals.
only since the combination of intra-BLA SB242084 and systemic fluvoxamine had no effect in normal animals. The results show that coapplication of intra-CeA SB242084 (10 μM) and systemic fluvoxamine (30 mg/kg) had no significant effect on audible and ultrasonic vocalizations to (normally) innocuous and noxious stimuli and on spinal reflexes in arthritic rats (n = 5 rats for each parameter).

**Discussion**

The novelty of this study is the finding that blockade of 5-HT2CR in the BLA, but not CeA, can induce or enhance the ability of an SSRI to inhibit emotional-affective pain behaviors in an animal model of arthritis pain. The results suggest that 5-HT2CR in the BLA prohibits beneficial pain-inhibiting effects of serotonin (5-HT), which is consistent with previous reports that 5-HT2CR in the amygdala (BLA but not CeA) contributes critically to anxiogenic behavior and anxiety disorders [16,69,77] and mediates anxiogenic side effects of antidepressants including SSRIs [4,70,78]. 5-HT2CR antagonists have anxiolytic and antidepressant effects [79-82], block the SSRI-induced increase of fear expression [71] and potentiate the antidepressant effects of SSRIs [83].

The present study provides not only further evidence for an important role of the amygdala in emotional-affective aspects of pain [26,27] but also identifies the serotonergic system as a powerful modulator of amygdala function in pain. Blockade of 5-HT2CR by itself had no effect, but increasing the serotonergic drive with an SSRI engaged this receptor so that its blockade allowed 5-HT to inhibit pain behaviors. Since this strategy affected supraspinally organized behaviors (vocalizations and anxiety-like behaviors) but not spinal reflexes, the beneficial 5-HT effects appear to be due to an action in the brain. Our data suggest that 5-HT2CR acts in the BLA to block pain-inhibiting effects of SSRIs. The synaptic and cellular mechanisms remain to be determined.
The amygdala receives serotonergic input predominantly from the dorsal raphe nucleus [63,64] and increased 5-HT release in the amygdala (BLA) is associated with aversive states [16,67,68]. 5-HT2CR activation in the BLA increased synaptic activation of BLA neurons [72]. A possibly scenario to explain the findings of our study is that 5-HT2CR activation drives BLA output to increase activity in the CeA, which serves as the output nucleus for major amygdala function and accounts for amygdala-dependent emotional-affective aspects of pain [26,27]. CeA neurons project directly or indirectly to brainstem and forebrain areas involved in the expression of aversive behaviors and pain modulation, including the periaqueductal gray [26,87-89]. Direct brainstem projections from CeA can be glutamatergic [90], but CRF-containing CeA neurons also include a population of GABAergic neurons [91,92]. Therefore, the positive correlation between amygdala output and pain behaviors can result from descending facilitation or disinhibition.

A single administration of fluvoxamine had pain-relieving effects in our study when combined with blockade of 5-HT2CR in the BLA, which is consistent with the observation that analgesic effects of anti-depressants are independent of their anti-depressant effects that usually

---

**Figure 4 Drug effects on anxiety-like behavior and locomotion.** Open-arm choice in the elevated plus maze (EPM) was measured for 5 min as the ratio of open-arm entries to the total number of entries expressed as % in sham controls (A) and arthritic animals (B). The combination of intra-BLA SB242084 (10 μM) and systemic fluvoxamine (30 mg/kg) had no effect in sham controls but increased the open-arm choice of arthritic rats significantly. *P < 0.05, compared to vehicle, one-way ANOVA followed by Dunnett’s multiple comparison tests). (C) Evaluation of locomotor activity (total number of entries into the 4 arms of the EPM) in sham controls (left bar) and arthritic animals for 30 min. Locomotor activity was decreased in arthritic rats. The different drug regimen tested in arthritic rats had no effect. Bar histograms show means ± SEM.
occur only after weeks [5,7]. Fluvoxamine alone had no effect except for a slight inhibition of ultrasonic vocalizations evoked by noxious stimulation in arthritic rats. Other studies reported weak effects of systemic fluvoxamine in the formalin pain test [93,94] and mixed effects in the hot plate test [93,95]. Intrathecal fluvoxamine had anti-allodynic effects in a neuropathic pain model (partial nerve ligation) and these were reduced by intrathecal administration of a 5-HT2A/2CR antagonist [96]. There is some evidence, however, that 5-HT2CR activation in the spinal cord may have inhibitory effects in neuropathic pain models [97,98], possibly mediated by indirect noradrenergic mechanisms [99]. Our data suggest that 5-HT2CR activation in the amygdala mediates undesirable effects of 5-HT.

Some technical aspects of our study deserve consideration. We used selective compounds at concentrations that are well established in the literature (SB242084 [22,100-102]; fluvoxamine [75,96]). However, while the drug concentration in the microdialysis fiber is known, the dose administered can only be estimated. Comparative data from our previous microdialysis and in vitro studies [45,55,58,84,85,103,104] indicate that the tissue concentration is at least 100 times lower than in the microdialysis probe due to the concentration gradient across the dialysis membrane and diffusion in the tissue. Therefore, drugs were dissolved in ACSF at a concentration 100 times that predicted to be needed. Microdialysis was chosen for drug delivery because it provides steady state drug levels without a volume effect [105]. Spread of the drug and site of action need to be considered. Drug application into the CeA had no effect. These placement control experiments suggest that the drug did not spread beyond a distance of 1 mm around the tip of the microdialysis probe to reach the BLA, which is consistent with our previous estimates [35,48,84,85]. The distance between the tips of the microdialysis probes in the BLA (effective drug administration site) and CeA (ineffective control site) is about 1 mm.

Conclusion
Pharmacological blockade of 5-HT2CR in the amygdala (BLA but not CeA) allows SSRIs to inhibit emotional-affective pain responses and anxiety-like behavior in an arthritis pain model. The study contributes novel insight into 5-HT functions in the brain and into brain mechanisms of pain.

Methods
Animals
Male Sprague Dawley rats (225–250 g) were housed in a temperature controlled room and maintained on a 12 h day/night cycle, with free access to food and water. On the day of the experiment, rats were transferred from the animal facility and allowed to acclimate to the laboratory for at least 1 h. At the end of the experiment, the animal was euthanized by decapitation using a guillotine (Harvard Apparatus Decapitator). All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Medical Branch (UTMB) and conformed to the guidelines of the International Association for the Study of Pain (IASP) and of the National Institutes of Health (NIH).
Arthritis pain model and sham controls
A localized mono-arthritis was induced in the left knee joint by intra-articular injections of kaolin (4%, 80–100 μl) and carrageenan (2%, 80–100 μl) through the patellar ligament. This treatment paradigm reliably leads to inflammation and swelling of the knee within 1–3 h, reaches a maximum plateau at 5–6 h, and persists for several days [106]. Therefore, the 5–6 h time point was selected for measuring behaviors and testing drug effects. In sham control rats, the syringe was inserted into the knee joint cavity under the same conditions as in arthritic animals except that no compound was injected. Vehicle was not injected in sham animals because intraarticular saline injection causes a temporary swelling of the joint [55], which is one of the cardinal symptoms of an inflammation. To avoid any latent effect of increased intraarticular pressure, vehicle (sterile saline) was not injected in sham animals.

Experimental protocol
On Day 1, a guide cannula for drug (or artificial CSF, ACSF) application by microdialysis was stereotaxically inserted into the right BLA or CeA. On Day 2, 5–6 h after the induction of arthritis (or needle insertion for shams), behavioral experiments were performed 30 min after the systemic (i.p.) injection of the fluvoxamine or its vehicle (0.9% NaCl solution) in combination with an intra-BLA or intra-CeA application of SB242084 (10 μM) into the CeA in combination with systemic administration of fluvoxamine (30 mg/kg, i.p) had no significant effect. Bar histograms show means ± SEM.

Drug application by microdialysis
Rats were deeply anaesthetized with pentobarbital sodium (Nembutal®, 50 mg/kg, i.p.) on Day 1. A guide cannula (David Kopf Instruments) was stereotaxically implanted into the right BLA or the right CeA, using the following coordinates: BLA, 2.8 mm caudal to bregma, 4.8 mm lateral to midline, 7.6 mm depth; CeA, 2.3 mm caudal to bregma, 4.0 mm lateral to midline, 7.0 mm depth [107]. Guide cannulas were affixed to the skull with dental acrylic (Plastic One, Roanoke, VA). Antibiotic ointment (Solosite Gel, Smith and Nephew) was applied to the exposed tissue to prevent infection. Local application of Lidocaine HCl (1%, 100 μl of 10 mg/ml) was done to minimize surgical pain and to prevent the animal from scratching of the surgical area.
upon recovery. On Day 2, a microdialysis probe (CMA/ Microdialysis 11, Solna Sweden) that extended 1 mm beyond the tip of the guide cannula, was inserted for stereotaxic drug application into the amygdala. The probe was connected to an infusion pump (Harvard Apparatus, Holliston, MA) using polyethylene-50 tubing. Drugs or ACSF (vehicle) were applied for 20 min at a rate of 5 μl/ min to establish equilibrium in the tissue. ACSF was oxygenated, equilibrated to pH 7.4 and contained the following (in mM): 125.0 NaCl, 2.6 KCl, 2.5 NaH₂PO₄, 1.3 CaCl₂, 0.9 MgCl₂, 21.0 NaHCO₃, and 3.5 glucose. SB242084 was dissolved in ACSF on the day of the experiment at a concentration 100-fold that predicted to be needed in the tissue based on data in the literature [22,100-102] because of the concentration gradient across the dialysis membrane and diffusion in the tissue [45,48,84,85]. At the end of the experiment, rats were decapitated and injection sites were verified histologically after injection of methylene blue (1 μl) and plotted on standard diagrams adapted from Paxinos and Watson [107] (see Figure 1).

Behavioral tests

Spinal reflexes

Thresholds of hindlimb withdrawal reflexes evoked by mechanical stimulation of the knee joint were measured as described in detail previously [106]. Mechanical stimuli of continuously increasing intensity were applied to the knee joint using a calibrated forceps equipped with a force transducer whose output was displayed (in g) on a screen. The area of tissue compressed by the tip of the forceps was 30 mm². Withdrawal threshold was defined as the minimum stimulus intensity that evoked a withdrawal reflex. The test was repeated twice (5 min intervals) and the values were averaged to calculate the threshold (force in g/30 mm²).

Audible and ultrasonic vocalizations

Vocalizations were recorded and analyzed as described in detail previously [42]. The experimental setup (U.S. Patent 7,213,538) included a custom-designed recording chamber, a condenser microphone (20 Hz to 16 kHz) connected to a preamplifier, an ultrasound detector (25 ± 4 kHz), filter and amplifier (UltraVox 4-channel system; Noldus Information Technology, Leesburg, VA), and data acquisition software (UltraVox 2.0; Noldus Information Technology), which automatically monitored the occurrence of audible and ultrasonic vocalizations within user-defined frequencies and recorded number and duration of digitized events. Vocalizations in the audible and ultrasonic ranges were recorded simultaneously but with different microphones (condenser microphone and ultrasound detector, respectively) connected to separate channels of the amplifier. This computerized recording system was set to ignore sounds outside the defined frequency range. Animals were placed in the recording chamber for acclimation 1 h before the vocalization measurements. The recording chamber ensured the stable positioning of the animal at a fixed distance from the sound detectors and allowed the mechanical stimulation of the knee joint through openings for the hindlimbs. Brief (15 s) innocuous (300 g/30 mm²) and noxious (1200 g/30 mm²) mechanical stimuli were applied to the knee, using a calibrated forceps (see “Spinal reflexes”). Total duration of vocalizations (arithmetic sum of the duration of individual events) was recorded for 1 min, starting with the onset of the mechanical stimulus. Audible and ultrasonic vocalizations reflect supraspinally organized nocifensive and affective responses to aversive stimuli [106,108].

Elevated plus maze test (EPM)

Anxiety-like behavior was determined using the EPM test as described previously [85,106]. The EPM (Columbus Instruments, OH) was constructed from stainless steel to facilitate inter-trial cleaning for elimination of odor cues. A central quadrangle (10 × 10 cm) connected two opposing open arms (50 cm long, 10 cm wide) and two opposing closed arms (50 cm long, 10 cm wide, with 40 cm high walls on both sides), arranged in the shape of a plus. The platform was elevated 70 cm above the floor. An automated photocell system (Multi-Varimex v.1.00; Columbus Instruments, OH, USA) recorded movements of the animal on a personal computer. At the beginning of each trial, the animal was placed onto the central quadrangle facing an open-arm. The EPM was inside a dark enclosure to minimize anxiety levels in the absence of pain. Anxiety-like behavior was determined by measuring the open-arm preference (ratio of open-arm entries to the total number of entries expressed as %) for 5 min. Animals that stayed only in one arm were excluded from experiment.

Statistical analysis

All averaged values are given as the mean ± standard error of the mean (SEM). GraphPad Prism 3.0 software (Graph-Pad, San Diego, CA) was used for all statistical analysis. For multiple comparisons, one-way analysis of variance (ANOVA) was used followed by Dunnett’s multiple comparisons tests. Statistical significance was accepted at the level P < 0.05.

Abbreviations

5-HT: Serotonin; BLA: Basolateral nucleus of the amygdala; CeA: Central nucleus of the amygdala; LA: Lateral nucleus of the amygdala; SSRI: Selective serotonin reuptake inhibitor.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SG and VN conceptualized the hypothesis and designed the study. SG carried out the experiments, analyzed data, prepared figures and wrote the
first draft of the manuscript. VN supervised the experiments, directed the data analysis, and finalized the manuscript. All authors read and approved the manuscript.

Acknowledgements
This work was supported by National Institute of Neurological Disorders and Stroke Grants NS-081121, NS-38261 and NS-11255.

Received: 28 June 2013 Accepted: 9 August 2013
Published: 12 August 2013

References
1. Avraay M, Myix E, Spence C. The sensory-discriminative and affective-motivational aspects of pain. Neurosci Biobehav Rev 2010, 34:214–223.
2. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol 2011, 93:385–404.
3. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012, 52:6–17.
4. Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Cell Tissue Res 2011, 6:298–308.
5. Perrot S, Javier RM, Marty M, Le JC, Laroche F. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford) 2008, 47:1117–1123.

Early life stress and pain: a meta-analysis. Pain Res Treat 2016, 2016:705602.

6. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent J, Krane EJ, LeBel AA, Levy RM, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85:533–548.

7. Citrome L, Weiss-Citrome A. Neuronal 5-HT receptors and pain. Eur J Neurosci 2008, 29:532–543.

8. Ferguson JM. SSR1 Antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Pract 2001, 3:22–27.

9. Osipov MH, Dusor GQ, Pomeca F. Central modulation of pain. J Pain Inv 2010, 120:3779–3787.

10. Fields HL, Heinricher MM, Mason P. Neuronal cell death in nociceptive sensory ganglia. Annu Rev Neurosci 1991, 14:219–245.

11. Nilsson MJ, Marin P, Bockaert J, la Cour CM. The amygdala and persistent pain. J Neurosci 2010, 30:9162–9167.

12. Perret S, Javier RM, Marty M, Le JC, Laroche F. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford) 2008, 47:1117–1123.

13. Citrome L, Weiss-Citrome A. Neuronal 5-HT receptors and pain. Eur J Neurosci 2008, 29:532–543.

14. Ferguson JM. SSR1 Antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Pract 2001, 3:22–27.

15. Hennon J, Hoyer DB. Molecular biology of 5-HT receptors. Behav Brain Res 2008, 195:198–213.

16. Jensen NH, Cremer TI, Sotty F. Therapeutic potential of 5-HT2C receptor ligands. Scientific World Journal 2010, 10:1870–1885.

17. Heilser LK, Zhou L, Bajwa P, Hsu J, Tecott LH. Serotonin 5-HT2C receptors regulate anxiety-like behavior. Genes Brain Behav 2007, 6:491–496.

18. Christianson JP, Ragole T, Arat J, Greenwood BN, Strong PV, Paul ED, Fleischer M, Watkins LR, Maier SF. 5-Hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. Biol Psychiatry 2010, 67:339–345.

19. Brach-Andersen C, Moller MU, Christiansen L, Thinggaard M, Otto M, Bosen K, Sindrup SH. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTTR2C) gene variants. J Neurochem 2010, 111:1311–1317.

20. Liu S, Babar MJ, Lefrancois ME, Hillman GR, Cunningham KA. Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction. Neuroscience 2007, 146:1667–1688.

21. Babar MJ, Stutz SJ, Cunningham KA. 5-HT2C receptors localize to dopamine and GABA neurons in the rat mesocaudal pathway. PLoS One 2011, 6:e20558.

22. Tardito D, Milanesi M, Bonifacino T, Musazzi L, Grilli M, Mallei A, Mocaer E, Gabriel-Gracia C, Racagni G, Popoli M, et al. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatoninergic and 5-HT2C receptor-dependent pathways. BMC Neurosci 2010, 11:68.
43. Martin TJ, Buchler NL, Kim SA, Ewan EE, Xiao R, Childers SR: Involvement of the lateral amygdala in the antiallodynic and reinforcing effects of heroin in rats after peripheral nerve injury. *Anesthesiology* 2011, 114:633–642.

44. Han JS, Li W, Neugebauer V: Critical role of calcinonin gene-related peptide 1 receptors in the amygdala in synaptic plasticity and pain behavior. *J Neurosci* 2003, 23:10777–10788.

45. Fu Y. Neugebauer V: Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. *J Neurosci* 2008, 28:3861–3876.

46. Fu Y, Han J, Ishola T, Scerbo M, Adwarinak H, Ramsey C, Neugebauer V: PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. *Mol Pain* 2008, 4:26–46.

47. Palazzo E, Fu Y, Li G, Maione S, Neugebauer V: Group III mGlur7 and mGlur8 in the amygdala differentially modulate nociceptive and affective pain behaviors. *Neuropharmacology* 2008, 55:337–545.

48. Ji G, Sun H, Fu Y, Li Z, Pain-Veira M, Galhardo V, Neugebauer V: Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation. *J Neurosci* 2010, 30:4541–5464.

49. Helbert MC, Adkordi D, Hennig A, Tamaki A, Blanchard DC, Blanchard RJ: Amygdala lesions produce analgesia in a novel, ethologically relevant acute pain test. *Phys and Behav* 1999, 67:99–105.

50. Liu CC, Ohara S, Franaszczuk P, Zagzoog N, Gallagher M, Lenz FA: Painful stimuli evoke potentials recorded from the medial temporal lobe in humans. *Neuroscience* 2010, 165:402–411.

51. Baliki MN, Geha PY, Jabbari K, Harden N, Schnitzler TJ, Apkarian AV: A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. *Neuroscience* 2010, 166:2353–2361.

52. Tillisch K, Mayer EA, Labus JS, Neugebauer V: The role of RNA editing of the serotonin 2C receptor in a rat model of affective pain behaviors. *J Neurosci Res* 2010, 91:1123–1133.

53. Kennett GA, Wood MD, Bright F, Tray B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, et al: SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist, displays a broad-based antidepressant and anxiolytic profile in rodent models and mouse models of anxiety. *Neuropharmacology* 1997, 36:793–802.

54. Schiess MC, Callahan PM, Zheng H: Serotonin 1B receptors within the nucleus of the amygdala. *Anesthesiology* 2010, 113:803–813.

55. Fu Y, Neugebauer V: Differential effects of mGlur7 and mGlur8 activation on pain-related synaptic activity in the amygdala. *Neuropharmacology* 2011, 61:1334–1344.

56. Ma QP, Yin GY, Ai MK, Han JS: Serotonergic projections from the nucleus raphe dorsalis to the amygdala in the rat. *Neurosci Lett* 1991, 134:21–24.

57. Lowry CA: Functional subsets of serotonergic neurons: implications for control of the hypothalamic-pituitary-adrenal axis. *J Neuroendocrinol* 2002, 14:911–923.

58. Stein C, Davidsen A, Albrecht D: 5-HT(1A) receptor-mediated inhibition and 5-HT(2) as well as 5-HT(3) receptor-mediated excitation in different subdivisions of the rat amygdala. *Synapse* 2000, 38:328–337.

59. Ranine DG: Serotonergic modulation of neurotransmission in the rat basolateral amygdala. *J Neurophyiol* 1999, 82:69–85.

60. Funada M, Hari C: Differential effects of psychological stress on activation of the 5-hydroxytryptamine-1A and dopamine-containing neurons in the brain of freely moving rats. *Brain Res* 2001, 901:247–251.

61. Mamede CE, Martinez RCR, de Souza Silva MA, Brandao ML: Increases in extracellular levels of 5-HT and dopamine in the basolateral, but not in the central, nucleus of amygdala induced by averse stimulation of the inferior colliculus. *Eur J Neurosci* 2005, 21:1131–1139.

62. Campbell BM, Merchant KM: Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. *Brain Res* 2003, 993:1–9.

63. Ravinder S, Pillai AG, Chatterji S: Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin reuptake inhibitor fluoxetine in rats. *Front Behav Neurosci* 2011, 5:88.

64. Burchhardt NS, Bush DE, McEwen BS, LeDoux JE: Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist. *Biol Psychiatry* 2007, 62:1111–1118.

65. Chen A, Hough CJ, Li H: Serotonin type II receptor activation facilitates synaptic plasticity via N-methyl-D-aspartate-mediated mechanism in the rat basolateral amygdala. *Neuroscience* 2008, 155:553–563.
88. Bourgeais L, Gauriau C, Bernard J-F: Projections from the nociceptive area of the central nucleus of the amygdala to the forebrain: a PHA-L study in the rat. Eur J Neurosci 2001, 14:229–255.
89. Gray TS, Magnuson DJ: Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992, 13:451–460.
90. Lee HS, Kim MA, Valentino RJ, Waterhouse BD: GLUTamate afferent projections to the dorsal raphe nucleus of the rat. Brain Res 2003, 96:57–71.
91. Veinante P, Stoeckel ME, Freund-Mercier MJ: GABA- and peptide-immunoreactivities co-localize in the rat central extended amygdala. Neurorep 1997, 8:2985–2988.
92. Day HE, Cumn EJ, Watson SJ Jr, Alé H: Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1beta. J Comp Neurol 1999, 413:113–128.
93. Otsuka N, Kuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A: Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth 2001, 15:141–158.
94. Yokogawa F, Kuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, Hosoyamada A: An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 2002, 95:63–68. table.
95. Schreiber S, Backer MM, Yanai J, Pick CG: The antinociceptive effect of fluvoxamine. Eur Neuropsychopharmacol 1996, 6:281–284.
96. Honda M, Uchida K, Tanabe M, Ono H: Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology 2006, 51:866–872.
97. Nakai K, Nakae A, Oba S, Sasaki M, Saito S, Goto F: 5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. Eur J Pain 2010, 14:999–1006.
98. Obata H, Ito N, Sasaki M, Saito S, Goto F: Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in rats with nerve injury. Pain 2004, 108:163–169.
99. Obata H, Ito N, Sasaki M, Saito S, Goto F: Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in the rats with peripheral nerve injury. Eur J Pharmacol 2007, 567:89–94.
100. Liu S, Cunningham KA: Serotonin(2C) receptors (5-HT(2C)R) control expression of cocaine-induced conditioned hyperactivity. Drug Alcohol Depend 2006, 81:275–282.
101. Zayara AE, Mover G, Valdivia PN, Lominac KA, McCreary AC, Szumlinski KK: Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology (Berl) 2011, 213:321–335.
102. Calcaigno E, Invernizzi RM: Strain-dependent serotonin neuron feedback control: role of serotonin 2C receptors. J Neurochem 2010, 114:1701–1710.
103. Li W, Neugebauer V: Differential roles of mGluR1 and mGluR5 in brief and prolonged nociceptive processing in central amygdala neurons. J Neurophysiol 2004, 91:19–24.
104. Li W, Neugebauer V: Block of NMDA and non-NMDA receptor activation results in reduced background and evoked activity of central amygdala neurons in a model of arthritic pain. Pain 2004, 110:12–122.
105. Stiller CO, Taylor BK, Linderoth B, Gustafsson H, Warsame Afrah A, Brodin E: Microdialysis in pain research. Adv Drug Deliv Rev 2003, 55:1065–1079.
106. Neugebauer V, Han JS, Advaniker H, Fu Y, Ji G: Techniques for assessing knee joint pain in arthritis. Mol Pain 2007, 3:8–20.
107. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. New York: Academic Press; 1998.
108. Borszcz GS, Leaton RN: The effect of amygdala lesions on conditional and unconditional vocalizations in rats. Neurobiol Learn Mem 2003, 79:212–225.